Abstract
Today, lung cancer is the most common cause of death from cancer in both men and women in the developed countries. An appropriate staging is of great value for patient’s management and prognosis. PET-CT is widely used in lung cancer because of its superiority, compared to other imaging modalities, in the detection of nodal and metastatic disease. PET-CT combines in one single method the detailed anatomic information provided by CT with the functional data provided by PET. 18F-FDG PET-CT currently is indicated for the characterization of lung lesions, staging of non-small cell lung carcinoma (NSCLC), detection of distant metastases, diagnosis of recurrent disease, planning radiotherapy, and treatment monitoring. PET-CT has proved to be a cost-effective method in the evaluation of lung cancer. In about 35% of cases first staged with CT, the stage of the disease has changed—in most cases the disease is upstaged—after subsequent PET-CT, with resultant changes in patient’s management. PET-CT is also a useful and promising method for the evaluation of SCLC—in selected cases—but its role remains under study.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bunyaviroch T, Coleman R (2006) PET evaluation of lung cancer. J Nucl Med 47(3):451–469
Fanti S, Franchi R, Batista G et al (2005) PET and PET-CT. State of the art and future prospects. Radiol Med 110:1–15
Ambrosini V, Nicolini S, Caroli P et al (2012) PET/CT imaging in different types of lung cancer: an overview. Eur J Radiol 81(5):988–1001
Vahid R, Dabbagh K (2007) Positron emission tomography (PET) in the management of lung cancer. Rev Pneumon 20(1):43–48
UyBico SJ’, Wu C, Suh R et al (2010) Lung cancer staging essentials: the new TNM staging system and potential imaging pitfalls. Radiographics 30:1163–1181
Kligerman S, Digumarthy S (2009) Staging of non–small cell lung cancer using integrated PET/CT. AJR 193(5):1203–1211
Czernin J, Schelbert H (2004) PET/CT imaging: facts, opinions, hopes, and questions. J Nucl Med 45((Supp l)):1S
Bradley J, Thorstad WL, Mutic S et al (2007) Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 59:4–5
Hanin FX, Lonneux M, Cornet J et al (2008) Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur J Cardiothorac Surg 33:819–823
Saif MW, Tzannou I, Makrilia N et al (2010) Role and cost effectiveness of PET/CT in management of patients with cancer. Yale J Biol Med 83:53–65
Fischer BM, Mortensen J, Langer SW et al (2006) PET/CT imaging in response evaluation of patients with small cell lung cancer. Lung Cancer 54:41–49
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Efthymiadou, R.D. (2018). PET-CT in Lung Cancer. In: Gouliamos, A., Andreou, J., Kosmidis, P. (eds) Imaging in Clinical Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-68873-2_31
Download citation
DOI: https://doi.org/10.1007/978-3-319-68873-2_31
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-68872-5
Online ISBN: 978-3-319-68873-2
eBook Packages: MedicineMedicine (R0)